Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions

Published:2021-03-24 Issue:6 Volume:9 Page:637-650
ISSN:2326-6066
Container-title:Cancer Immunology Research
language:en
Short-container-title:Cancer Immunol Res

Author:

Hajaj Emma,Zisman Elad,Tzaban Shay,Merims Sharon,Cohen Jonathan^ORCID,Klein Shiri,Frankenburg Shoshana,Sade-Feldman Moshe,Tabach Yuval,Yizhak Keren^ORCID,Navon Ami,Stepensky Polina,Hacohen Nir,Peretz Tamar^ORCID,Veillette André,Karni Rotem,Eisenberg Galit,Lotem Michal

Funder

Perlstein family fund

Deutsche Forschungsgemeinschaft

Melanoma Research Alliance

Israel Science Foundation

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Israel Cancer Research Fund

Rosetrees Trust

Gouvernement du Canada | CIHR | Institute of Health Services and Policy Research

International Development Research Centre

Azrieli Foundation

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Immunology

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Network-based analysis of heterogeneous patient-matched brain and extracranial melanoma metastasis pairs reveals three homogeneous subgroups;Computational and Structural Biotechnology Journal;2024-12

2. Protein isoform-centric therapeutics: expanding targets and increasing specificity;Nature Reviews Drug Discovery;2024-09-04

3. Comparative characterization of two monoclonal antibodies targeting canine PD-1;Frontiers in Immunology;2024-05-08

4. A review: Mechanisms and molecular pathways of signaling lymphocytic activation molecule family 3 (SLAMF3) in immune modulation and therapeutic prospects;International Immunopharmacology;2024-05

5. Deciphering the role of alternative splicing in neoplastic diseases for immune-oncological therapies;Frontiers in Immunology;2024-04-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3